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Involvement of the HLXB9 Homeobox Gene in
Currarino Syndrome
To the Editor:
Anorectal malformations (ARMs) are among the most
common congenital anomalies, accounting for 25% of
digestive malformations that require neonatal surgery.
ARMs have been found associated with sacral anomalies
∼29% of the time (Rich et al. 1988). When ARMs are
combined with lumbosacral anomalies, they fall into the
spectrum of the caudal regression syndrome (CRS),
which can also exhibit additional features such as partial
or total sacrococcygeal agenesis, neural changes, and
urogenital malformations (Lerone et al. 1997). The in-
cidence of CRS is ∼1 in 7,500 (Kallen et al. 1974). A
detailed clinical characterization of patients affected by
ARMs with partial or total sacrococcygeal agenesis re-
vealed significant differences in the phenotypes, leading
to the differentiation of five specific categories (Kalitzki
1965; Cama et al. 1996): (1) total sacral agenesis with
normal or short transverse pelvic diameter and some
lumbar vertebrae possibly missing (fig. 1a and b), (2)
total sacral agenesis without involvement of lumbar ver-
tebrae, (3) subtotal sacral agenesis or sacral hypodev-
elopment (with S1 present), (4) hemisacrum (fig. 1c), and
(5) coccygeal agenesis.
In 1981, Guido Currarino described a form of CRS
with hemisacrum (type IV sacral malformation), ano-
rectal malformation, and presacral mass (anterior men-
ingocele, teratoma, and/or rectal duplication) (fig. 1d;
Currarino et al. 1981). The Currarino syndrome (CS;
also called “Currarino triad”) was observed to segregate
in an autosomal dominant manner that often displayed
phenotypic variability. As defined in the original reports,
patients affected by true CS always exhibit the typical
hemisacrum, with intact first sacral vertebra (sickle-
shaped sacrum), which makes this specific sacral anom-
aly distinct to this syndrome.
Genetic studies suggested that a locus involved in nor-
mal sacral and anorectal development mapped to the
terminal end (q36) of human chromosome 7 (Lynch et
al. 1995; Seri et al. 1999). Mutations within the HLXB9
gene were identified in six cases, collectively grouped as
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Figure 1 a, ARM with total sacral agenesis and L5 hypoplasia in patient 020. b, Distal cologram, showing presence of a rectobulbar
fistula. c and d, Hemisacrum as observed in CS (c) and in patient 015 (d). The MRI shows the presence of the anterior meningocele (AM).
having dominantly inherited sacral agenesis (Ross et al.
1998). To define a more precise involvement of HLXB9
in the different phenotypic subgroupings of ARMs as-
sociated with sacral abnormalities, we screened for the
presence of mutations in 27 individuals showing differ-
ent sacral conditions, as described in table 1.
The HLXB9 gene contains three exons: double-
gradient–denaturing gradient-gel electrophoresis (DG-
DGGE) (Cremonesi et al. 1997) was performed on exons
2 and 3 (the homeodomain is coded by a portion of
these two exons) (fig. 2). Patients showing an abnormal
electrophoretic pattern were further analyzed by DNA
sequencing (see conditions in the note to table 1). The
DG-DGGE methodology yielded a high mutation-detec-
tion efficiency for exons 2 and 3, as reported elsewhere
for the analysis of other genes (Cremonesi et al. 1999).
Nevertheless, because of an extremely high melting pro-
file for exon 1, it was necessary to sequence it in all 27
samples.
Analysis of the HLXB9 coding region and intron-exon
Table 1
Collection of Patients with Anorectal and Sacral Anomalies in This Study
Patient
(Sex)
Clinical Diagnosis
(Category) Sacral Phenotypea Associated Anomalies
HLXB9 Status/Pre-
dicted Protein Change
CGC
Status
001 (F) CS (IV) Hemisacrum ARM with rectoperi-
neal fistula, presacral
teratoma, tethered
cord, anterior
meningocele
Apparent hemizygous
deletion of HLXB9
11/del
002 (F) CS (IV) Hemisacrum ARM with rectoperi-
neal fistula, anterior
meningocele
384delG (exon 1)/trun-
cated protein
11/11
011 (F) CS (IV) Hemisacrum ARM with rectoperi-
neal fistula, tethered
cord, anterior menin-
gocele, hydromyelia
R295W (exon 3/a),
amino acid substitu-
tion within
homeodomain
11/9
015 (M) CS (IV) Hemisacrum ARM with rectoperi-
neal fistula, anterior
meningocele
Not detected 11/11
019 (M) CS (IV) Hemisacrum ARM without fistula,
hyposadia, Down
syndrome
Not detected 11/9
059 (F) CS (IV) Hemisacrum ARM with rectoperi-
neal fistula, decreased
bladder capacity
85811GrA (exon 2)/
splicing defect
11/11
060 (F) CS (IV) Hemisacrum ARM with rectoperi-
neal fistula
T248S (exon 2)/amino
acid substitution
within the
homeodomain
11/11
066 (F) CS (IV) Hemisacrum ARM with rectoperi-
neal fistula, presacral
teratoma
Not detected 11/11
069 (F) CS (IV) Hemisacrum ARM, tethered cord,
presacral mass, rectal
duplication, bifid clit-
oris,lipoma of conus,
holoprosencephaly
Hemizygous deletion of
HLXB9
12/del
070 (M) CS (IV) Hemisacrum ARM, presacral mass Hemizygous deletion of
HLXB9
11/del
003 (M) CRS (III) Agenesia of coccix
and one sacral ver-
tebra; SR = .43
ARM with rectobulbar
fistula, lipoma of fi-
lum, hydromyelia,
vertebral anomalies
(L3–L4), syndactyly
of second and third
toes
Not detected 11/11
004 (M) CRS (III) Agenesia of coccix
and one sacral ver-
tebra; SR = .70
ARM with rectobulbar
fistula, bilateral vesi-
coureteral reflux, ver-
tebral anomalies
(L2–L5)
Not detected 11/11
007 (M) CRS (III) SR = .55 ARM with rectopros-
tatic fistula, lipoma
of terminal filum, hy-
dromyelia, tethered
cord, intra-atrial de-
fect, pulmonary ar-
tery stenosis, syndac-
tyly of the third and
fourth fingers
Not detected 11/11
014 (M) CRS (III) CRS; SR = .45 ARM with rectovesical
fistula
Not detected 11/11
(continued)
Table 1 Continued
Patient
(Sex)
Clinical Diagnosis
(Category) Sacral Phenotypea Associated Anomalies
HLXB9 Status/Pre-
dicted Protein Change
CGC
Status
016 (F) CRS (III) Agenesia of coccix and
one sacral vertebra; SR =
.35
ARM with rectocloacal
fistula, duplication of
uterus and vagina
Not detected 11/11
018 (M) CRS (III) CRS ARM with rectobulbar
fistula, posterior
meningocele
Not detected 11/11
024 (F) CRS (III) SR = .24 ARM with rectocloacal,
lipoma of terminal fi-
lum, tethered cord,
right ureterocele, in-
tra-abdominal testis,
bilateral congenital
clubfoot
Not detected 11/10
025 (M) CRS (III) Agenesia of coccix and one
sacral vertebra; SR = .54
ARM with rectobulbar
fistula, intra-ventricu-
lar defect
Not detected 11/8
029 (F) CRS (III) Agenesia of coccix and three
sacral vertebrae; SR = .33
ARM with rectoperi-
neal fistula, high
medullary cone
(D11), vertebral fu-
sion (L4–L5), annu-
lar pancreas, inferior
limb arthrogryposis,
bilateral congenital
clubfoot
Not detected 11/11
030 (F) CRS (III) Agenesia of coccix and one
sacral vertebra; SR = .58
ARM with rectocloacal
fistula, tethered cord,
L5 schisis, bicornate
uterus
Not detected 11/11
031 (F) CRS (III) SR = .54 ARM with rectovesti-
bular fistula,
macrocrania
Not detected 11/11
033 (F) CRS (III) SR = .55 ARM with rectovesti-
bular fistula, thick-
ened filum terminale,
tethered cord,
hemangiomatosis
Not detected 11/9
035 (F) CRS (III) SR = .56 ARM with rectobulbar
fistula, mild atrophy
of cerebral cortex,
hypoparathyroidism
Not detected 11/11
036 (M) CRS (III) Agenesia of coccix; SR = .54 ARM with rectobulbar
fistula, low medullary
cone (L4), open fora-
men ovale, right Hy-
dronephrosis, anoma-
lies of cervical spine
and first right rib
Not detected 11/11
068 (F) CRS (III) SR = .27 ARM with rectocloacal
fistula, monolateral
renal dysgenesis
Not detected 11/11
009 (M) Sacral agenesis (I) Complete sacral agenesis ARM with rectopros-
tatic fistula, high
medullary cone
(D11), hydromyelia,
right multicystic kid-
ney, left mega-ureter,
right hernia and un-
descended testis
Not detected 11/11
(continued)
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Table 1 Continued
Patient
(Sex)
Clinical Diagnosis
(Category) Sacral Phenotypea Associated Anomalies
HLXB9 Status/Pre-
dicted Protein Change
CGC
Status
020 (M) Sacral agenesis (I) Agenesis of sacral
vertebrae and
one lumbar
vertebra
ARM with rectobulbar
fistula, bilateral con-
genital clubfoot,
monolateral renal
dysgenesis,
hypospadias
Not detected 11/11
NOTE.—In the familial cases (001, 015, 059, and 060) where mutations are detected, they segregate with the phenotype. The exception is
the mother of patient 060, who has the T248S change but no detectable phenotype. The following polymorphic markers were used to define
the extent of the deletion in patients 069 and 070: cen-NOS3-D7S1829-GATAP6678-D7S1491-D7S798-D7S2546-AFM175yg1-D7S637-
D7S2462-D7S550-SHH-D7S2465-D7S559-HLXB9-D7S2423-D7S594-tel (see Chromosome 7 Database; for a high-resolution map around SHH
and HLXB9, see the work of Belloni et al. [1996] and Heus et al. [1999]). The breakpoints in patients 069 and 070 were located between
markers D7S550–D7S2465 (centromeric) and D7S2423–D7S594 (telomeric) and between markers NOS3–D7S1829 (centromeric) and
D7S2423–D7S594 (telomeric), respectively, indicating that HLXB9 was deleted in both patients. DG-DGGE conditions were as follows: exon
2—60%–100% urea-formamide (in all cases, 7M urea and 40% formamide represent the 100% denaturant), 6.5%–12% acrylamide, 75 V,
16 h, for primers HB9-2F (5′-TGTAGTGGTACAATCAGCAACGGGA-3′) and HB9-2R (5′-GCCCGCCCCCGCCGCCCTGCCCGCGCCCC-
GCGCCGCCCGCTCGCCGCCCGCCGCCCGCAAAGGTAACAGTGTCCCATGGGA-3′) (351-bp product); the PCR was 947C for 5 min (1
cycle); 947C for 1 min, 607C for 45 s, and 727C for 1 min (35 cycles); and 727C for 10 min (1 cycle); exon 3/a—40%–90% urea, 6.5%–15%
acrylamide, 50 V, 14 h, for primers HB9-3/aF (5′-GCCCGCCCCCGCCGCCCTGCCCGCGCCCCGCGCCGCCCGCTCGCCGCCCGCCGCC-
CCCCTTCTGTTTCTCCGCTTCCTGCG-3′) and HB9-3aR (5′ CACCCTGAGGCCATTCCAGGGCCGA-3′) (266-bp product); the PCR was
947C for 5 min (1 cycle); 947C for 1 min, 607C for 45 s, and 727C for 1 min (35 cycles); and 727C for 10 min (1 cycle); exon 3/b—30%–100%
urea, 10%–15% acrylamide, 65 V, 20 h, for primers HB9-3/bF (5′CCCGCCGCCCGCCGCTCGCCCGCCGCGCCCCGCGCCCGTCCCG-
CCGCCCCCGCCCAAAAAAGGCCAAAGAGCAGG-3′) and HB9-3/bR (5′-TGCGGGCGCCGGGGCCTCCGGGAGA-3′) (446-bp product).
The PCR was 947C for 5 min (1 cycle); 947C for 1 min, 627C for 45 s, and 727C for 1 min (35 cycles); and 727C for 10 min (1 cycle). Primer
pairs used for amplification and sequencing of exon 1 (with an ABI-373) were HB9-1F (5′-CCGCACACGGCCGCGTCGCCCGCCACCGGG-
3′) and HB9-1R (5′-CGGCGGCGGCAGCGGCCGCTGCGCCCGGAT-3′) (439-bp product) (the PCR was 947C for 5 min [1 cycle]; 947C for
1 min, 607C for 45 s, and 727C for 1 min [35 cycles]; and 727C for 10 min [1 cycle]) and HB9-1FaM13 (5′-TGTAAAACGACGGCCA-
GTCGGCACGGGCGGCGGGCACGGGGGGCCCCA-3′) and HB9-1Rc (5′-GCAGCTCTTCCCCCGCTCGCTGGGAGCCAA-3′) (518-bp
product); the PCR was 947C for 5 min (1 cycle); 947C for 1 min, 627C for 45 s, and 727C for 1 min (35 cycles); and 727C for 10 min (1 cycle).
PCR-mediated site-directed mutagenesis experiments were designed to detect the 384delG mutations by use of the following primers: HB9-1F-
PSDM (5′-GCCCGCCGACCGCCTGCGCGCCGAGAGGCC-3′) and HB9-1R (179-bp product); the PCR was 947C for 5 min (1 cycle); 947C
for 1 min, 587C for 45 s, and 727C for 1 min (30 cycles); and 727C for 10 min (1 cycle). StuI restriction digestion of the precipitated PCR
products recognizes the presence of the restriction site only on the mutated allele (50 ml of PCR product were precipitated and digested with
StuI; undigested fragment, 179 bp; digested fragments, 28 and 151 bp). Analysis was on a 2% agarose/1% Nu-Sieve gel. Each PCR reaction
was performed on 500 ng of genomic DNA in a 50-ml volume containing 50 pmol of each primer, 400 mmol of each dNTP, 10% dimethyl
sulfoxide, 1 U of Dynazyme DNA polymerase, 10 mM TRIS-HCl (pH 8.8), 1.5 mM MgCl2, 50 mM KCl, and 1.5% Triton X-100. Analysis
of the CGC repeat coding for the polyalanine tract was accomplished by PCR of the region (Eppendorf Pfu), followed by electrophoresis on
6% polyacrylamide. Primers HB9-1Fa and HB9-1Rrep (5′-AGGGTGCAGCCCCAGCGCCAGGCC-3′) were used. One of the two primers was
end-labeled with g[32P]-dATP, by means of NEB T4 kinase (in a 10-ml reaction: primer, 100 pmol; T4 kinase, 5 U; T4 buffer, 1 ml; and g[32P]-
dATP, 10 mCi; the labeling was for 1 h at 377C, followed by precipitation such that the primer was at the final concentration of 4 pmol/ml);
the PCR was 947C for 5 min (1 cycle); 947C for 1 min, 607C for 45 s; and 727C for 1 min (30 cycles); 607C for 45 s; and 727C for 10 min (1
cycle) and was performed on 250 ng of genomic DNA in a 25-ml reaction mixture containing 4 pmol of labeled primer, 20 pmol of unlabeled
primer, 400 mmol of each dNTP, 10% dimethyl sulfoxide, and 1.25 U of Pfu, 20 mM TRIS-HCl (pH 8), 2 mM MgCl2, 10 mM KCl, 6 mM
(NH4)2SO4, 0.1% Triton X-100, and 10 mg nuclease-free BSA/ml. Four microliters of each reaction was run on polyacrylamide gels for 4 h at
1,800 V. M13mp18 sequence was used as a length control for the PCR product that was 124 bp in the presence of the CGC11 repeated unit.
a SR = sacral ratio. This is obtained by comparison of the sacrum size with the fixed bony parameter of the pelvis, creating a ratio between
different segments (Pena 1995); the normal SR is .77.
boundaries in our cohort of patients detected mutations
in only those clinically characterized to have CS. Four
patients (002, 011, 059, and 060) harbored, within the
coding sequence, heterozygous point mutations that
would be predicted to cause deleterious changes in the
protein (table 1). The entire HLXB9 gene in two patients
(069 and 070) and possibly a third (001; see below) was
found to be deleted. For each mutation, a similar change
was not observed in any of 100 normal chromosomes
examined either through DG-DGGE (T248S, 858
11GrA, R295W) or PCR-mediated site-directed mu-
tagenesis (384delG) (Haliassos et al. 1989). DG-DGGE
of exon 2 detected the presence of an abnormal pattern
in 1 of 100 normal and 1 of 54 patient chromosomes
examined: direct sequencing showed that the sequence
variation is intronic and not involved in the splicing.
Moreover, the DNA sequence of exon 1 in patient 059,
already affected by the 85811GrA mutation, con-
tained, at position 357, a second nucleotide change,
which does not cause an amino acid change (P119P).
Letters to the Editor 317
Figure 2 Example of DG-DGGE (a) and direct DNA sequencing
(b). a, Lanes A and B, Replicated samples frm patient 060. Lanes C
and D, Controls. b, Electrophoregram showing two peaks (marked
with an asterisk [*]) at the T248S mutation in patient 060.
The missense mutations all affect the homeodomain,
suggesting that an amino acid change in this region is
relevant to the normal functioning of the protein. The
85811GrA mutation affects a nucleotide in the donor
splicing site, which is 100% conserved, suggesting that
an abnormal protein will be obtained in this case.
We also analyzed the region of exon 1, coding for the
16-alanine stretch, since variation in polyalanine resi-
dues has been reported in other homeobox genes in-
volved in disease (Goodman et al. 1997; Mundlos et al.
1997; Brais et al. 1998). This region, which includes a
CGC repeat, was examined to test if length variation
was associated with any phenotype in our collection (87
unaffected individuals, or 174 chromosomes, served as
controls). We determined that the CGC11 allele was the
most common in the general population, accounting for
the 90.23% of the chromosomes analyzed. Other alleles
observed were CGC12 (1.7%), CGC9 (7.47%), and
CGC8 (0.6%), and these were all heterozygous changes.
Only one sample (including both affected individuals
and controls) revealed a homozygous change in the po-
lyalanine tract (CGC9/CGC9). Although this sample was
from the control collection, closer investigation revealed
that the individual lacked fusion of the posterior arch
of the vertebrae and had scoliosis on the left side. No
association between the CGC-repeat length and the pres-
ence of sacral malformations could be established, since
the alleles observed in the 27 patients were all detected
in controls.
The CGC-repeat length was important in the analysis
of CS sample 001, the one family, of our collection,
demonstrating linkage to 7q36 (Seri et al. 1999). In this
family, the CGC9 allele has not been passed from the 2d
to the 3d generation, which suggests that a microdeletion
involving HLXB9 or an expansion of the allele from
CGC9 to CGC11 was present in two affected brothers of
the 2d generation and then was transmitted to their de-
scendants. Since an expansion would not likely be path-
ogenic (on the basis of our other findings), it is more
likely that a microscopic deletion occurred. FISH anal-
ysis, with BACs and cosmids encompassing HLXB9, give
the expected two signals on metaphase analysis (data
not shown), which would suggest that the microdeletion
is small. In three patients with CS (015, 019, and 066),
no DNA sequence alterations were detected.
Therefore, we identified HLXB9 mutations in only
those individuals diagnosed as having CS. This obser-
vation is not inconsistent with the findings of the original
report (Ross et al. 1998), which described six different
mutations in unrelated individuals who either were di-
agnosed with CS or had partial characteristics reminis-
cent of CS. (These patients, however, were all collectively
grouped as having sacral agenesis.) Instead, it refines the
involvement of HLXB9 in specific anorectal and sacral
malformations. Thus, we have not been able to dem-
onstrate a role for HLXB9 in caudal regression (cate-
gories III and V) and total sacral agenesis (categories I
and II). Although it is possible that a mutation or DNA
sequence variation in the noncoding region of HLXB9
could be present in these individuals, it is perhaps more
likely that these malformations are due to other factors
or defects in other gene(s). In three patients with CS
(015, 019, and 060), no mutation could be found, which
suggests genetic heterogeneity in CS or some other non-
genetic determinant (since these cases are all sporadic
and not familial). To our knowledge, no linkage studies
of families affected exclusively by CRS or total sacral
agenesis have been reported so far. The use of mouse
models to study the human disease will likely be limited,
since mice homozygous for a null mutation in Hlxb9
apparently fail to show any sacral defect (Harrison et
al. 1999; Li et al. 1999)
In the mutation screen, we paid particular attention
to the polyalanine region in exon 1, since variation in
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lengths of these tracts in other homeodomain genes have
been described in specific pathologies such as synpoly-
dactyly (Mundlos et al. 1997), oculopharyngeal mus-
cular dystrophy (Brais et al. 1998), and cleidocranial
dysplasia (Goodman et al. 1997). Although we could
determine that the CGC11 allele was the most common
in the population (∼90%), there was no specific corre-
lation with any heterozygous variants (which led to ei-
ther an increase or a decrease in CGC length) in the
sacral conditions studied. A homozygous reduction in
the length of the repeat (CGC9/CGC9) was identified in
a single control sample, and, although this individual
exhibited spinal anomalies, a clear correlation could not
be established and will require further investigation.
In most ARMs and sacral-defect cases, the cause is
unknown, and no familial recurrence is noted. In spite
of the small number of familial cases reported, it is pos-
sible that specific genes cause defined phenotypes. In this
study, we have presented evidence that the HLXB9 may
be exclusively involved in CS. This observation is im-
mediately relevant for clinical investigation and genetic
screening, and the criteria and protocols to perform these
studies have been outlined in this report.
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A Novel Locus for Leber Congenital Amaurosis Maps
to Chromosome 6q
To the Editor:
Leber congenital amaurosis (LCA) (MIM 204000/
204100) is a clinically and genetically heterogeneous ret-
inal disorder that occurs in infancy and is accompanied
by profound visual loss, nystagmus, poor pupillary re-
flexes, and either a normal retina or varying degrees of
atrophy and pigmentary changes (Leber 1869, 1871;
Franc¸ois 1968). The electroretinogram (ERG) is extin-
guished or severely reduced (Franceschetti 1954). LCA
is largely a recessive disease, although autosomal dom-
inant pedigrees have been identified (Sorsby et al. 1960;
Heckenlively 1988). To date, three genes for LCA have
been identified and sequenced: retinal guanylate cyclase
(GUCY2D) on chromosome 17p13; retinal pigment ep-
ithelium protein (RPE65) on chromosome 1p31; and
cone-rod homeobox (CRX) on chromosome 19q13.3.
One additional locus has been identified on chromosome
14q24 (Stockton et al. 1998). We show evidence for
linkage to chromosome 6q11-16 in a multigenerational
kindred of Old Order River Brethren. The disease gene
maps to a 23-cM interval flanked by DNA polymorphic
markers D6S1551 and D6S1694, with a maximum two-
point LOD score of 3.38 (recombination fraction [v]
zero) at D6S391. Two candidate genes on chromosome
6 were screened for mutations: gamma aminobutyric
acid rho1 and rho2 (GABRR1 and GABRR2) at 6q14-
21 (Cutting et al. 1992), and interphotoreceptor matrix
proteoglycan (IMPG1) at 6q13-15 (Gehrig et al. 1998).
The incidence of LCA is 3 in 100,000 persons and
accounts for >5% of all inherited retinal dystrophies
(Perrault et al. 1996). Clinical and genetic heterogeneity
have been demonstrated (Wardenburg 1961; Camuzat
et al. 1996). The phenotype has been associated with
familial juvenile nephronophthisis and cone-shaped
epiphyses (Saldino-Mainzer syndrome) and with kidney
disease (Senior-Loken syndrome), osteoporosis, meta-
bolic diseases, and neurological abnormalities (Loken et
al. 1961; Senior et al. 1961; Dekaban 1969; Mainzer et
al. 1970; Ellis et al. 1984).
The first locus for LCA was mapped to 17p13 with
the use of homozygosity mapping in consanguineous
families of North African descent (Camuzat et al. 1996).
Mutations in the retina-specific guanylate cyclase gene
(RETGC 1), on chromosome 17p13, involved in pho-
totransduction, were subsequently identified (Perrault et
al. 1996). Mutations in RPE65 on chromosome 1p31,
specific to the retinal pigment epithelium involved in
retinoid metabolism, were reported in patients with
LCA, thus establishing a second gene (LCA2) for this
heterogeneous disease (Marlhens et al. 1997). The pho-
toreceptor-specific homeobox gene CRX, on chromo-
some 19q13.3, has been implicated as the third gene,
since mutations were demonstrated (Freund et al. 1998).
A novel locus on chromosome 14q24 (LCA3) was iden-
tified in consanguineous Saudi Arabian families (Stock-
ton et al. 1998).
We studied a consanguineous family belonging to the
Old Order River Brethren, a religious isolate originating
in eastern Pennsylvania. The Old Order River Brethren
descended from the Swiss, who emigrated to America in
the 1750s in pursuit of religious freedom (Breckvill
1972). The kindred includes three affected individuals
in two related sibships (fig. 1) who were initially eval-
uated at the Johns Hopkins Center for Hereditary Eye
Diseases (JHCHED) and who are being followed an-
nually. The patients presented with visual acuities in the
order of 20/100–20/400, nystagmus, high hypermetro-
pia, poor pupillary reflexes, and normal fundi. Progres-
sive hypermetropia and increasing peripheral retinal
mottling, of varying degree, were noted. The ERG was
abolished. Review of other systems was unremarkable.
We report a novel locus for LCA (LCA5) in this pedigree,
on chromosome 6q11-16, by linkage analysis and ho-
mozygosity mapping.
Venous blood samples were obtained from 27 family
members of the Old Order River Brethren community
and a cheek brush sample was obtained from an infant
(individual 29). Consents were obtained in accordance
with regulations of the Johns Hopkins Medical Insti-
tutions’ Joint Committee on Clinical Investigation. DNA
was isolated from whole blood by means of the QIAamp
Blood Kit (Qiagen), according to the manufacturer’s in-
